Cen Guo

7PUBLICATIONS
46CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersPharmaceutical delivery technologiesPharmacogenomicsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Sep 04, 2026
A Phase 1 Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients With Advanced Gastrointestinal Cancers.

|Aug 14, 2026
Population Pharmacokinetics and Exposure-Response Analyses to Support Cofetuzumab Pelidotin (ABBV-647) Dose Optimization in Non-Small Cell Lung Cancer Patients.

|Jun 13, 2026
AI-Powered Lesion-Level Tumor Growth Inhibition Modeling Improves Model Stability and Prognostic Association With PFS.

|Dec 11, 2025
Talazoparib Formulation Bridging in Cancer Patients-Challenges and the Critical Role of Model-Informed Drug Development in Approval Despite Failed Bioequivalence.

Diane Wang, Cathy Cen Guo, Xizhe Gao

|Nov 17, 2022
PK/PD model-informed dose selection for oncology phase I expansion: Case study based on PF-06939999, a PRMT5 inhibitor.

Cen Guo, Kai H Liao, Meng Li

|Oct 27, 2022
First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors.

Omid Hamid, Alberto A Chiappori, John A Thompson

Pageof 2

Frequent Collaborators

2 joint publications

Kevin Maresca

1 joint publications

Marwan Fakih

1 joint publications

Toshihiko Doi

1 joint publications

Anthony Tolcher